Jikeqin (semaglutide SC once-weekly biosimilar)
/ Huadong Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 26, 2026
China’s Jiuyuan Genetic seeks approval for Wegovy biosimilar
(WKZO)
- "Jiuyuan said results of a Phase III trial in subjects with obesity showed Jikeqin was 'clinically equivalent' to a reference drug in terms of its safety profile, and in the percent change in patient body weight from baseline after 44 weeks after treatment."
China filing • Obesity
1 to 1
Of
1
Go to page
1